title: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.
abstract: Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).
authors: Division of Nephrology Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.|Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
authors: K A
authors: KA
authors: Birdwell
authors: Division of Nephrology and Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
authors: B
authors: B
authors: Decker
authors: Department of Genetics, Stanford University, Stanford, California, USA.
authors: J M
authors: JM
authors: Barbarino
authors: Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.|Department of Biomedical Informatics, Vanderbilt University, Nashville, Tennessee, USA.
authors: J F
authors: JF
authors: Peterson
authors: Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.|Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
authors: C M
authors: CM
authors: Stein
authors: Center for Pharmacogenomics, School of Medicine, The Ohio State University, Columbus, Ohio, USA.
authors: W
authors: W
authors: Sadee
authors: Center for Pharmacogenomics, School of Medicine, The Ohio State University, Columbus, Ohio, USA.
authors: D
authors: D
authors: Wang
authors: Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.|Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
authors: A A
authors: AA
authors: Vinks
authors: Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, Peoples Republic of China.
authors: Y
authors: Y
authors: He
authors: Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
authors: J J
authors: JJ
authors: Swen
authors: Division of Clinical Pharmacology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, USA.
authors: J S
authors: JS
authors: Leeder
authors: Department of Clinical Chemistry, Erasmus MC Rotterdam, The Netherlands.
authors: Rhn
authors: R
authors: van Schaik
authors: Department of Pharmaceutics, University of Washington, Seattle, Washington, USA.
authors: K E
authors: KE
authors: Thummel
authors: Department of Genetics, Stanford University, Stanford, California, USA.
authors: T E
authors: TE
authors: Klein
authors: Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
authors: K E
authors: KE
authors: Caudle
authors: Institute of Medical and Biomedical Education, Renal Medicine, St. George's, University of London, London, UK.
authors: I A M
authors: IA
authors: MacPhee
mesh_terms: D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D005820:Genetic Testing; D005838:Genotype; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016377:Organ Transplantation; D016559:Tacrolimus / Q000008:administration & dosage*
chemical_list: D007166:Immunosuppressive Agents; D051544:Cytochrome P-450 CYP3A; D016559:Tacrolimus